Skip to main content

Ecallantide News

FDA Approves Expanded Use of Kalbitor for the Treatment of HAE to Patients 12 Years of Age and Older

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Kalbitor (ecallantide),...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Ecallantide patient information at Drugs.com